Thank you for your contributions to the Future of Longevity Impact Roadmap! The discussions in this community have helped XPRIZE understand the challenges that need to be overcome to extend human lifespans and identify potential breakthroughs in longevity.

The Impact Roadmap is now complete. You can browse the interactive version on the XPRIZE website and download the full report.

The discussion forums about obstacles to long life, innovations in life extension and breakthroughs in longevity will be closed, but alumni of this project are invited to join the Future of Longevity Group to continue the conversation and stay in touch.

Expedited Clinical Trials

XPRIZEXPRIZE Los Angeles, CaliforniaPosts: 108 admin

This breakthrough would accelerate clinical trials through using constant monitoring technologies like portable diagnostics, robotics, and wearable computing elements. These devices will collect real-time data and information about participants in clinical trials, and thereby make the process of testing a treatment’s efficacy and safety much faster.


Acceleration of clinical trials would help reduce the barriers to drug discovery and testing (and thus promote accessibility). The data collected could help inform a unified theory of aging, and also the development of personalized treatments.

Relevant Technologies and Techniques
  • Sensors
  • 5G internet (for data sharing)
  • Crowdsourcing (for funding and data collection)
  • Open source (for data sharing)
  • Personalization of treatments


  • NickOttensNickOttens Barcelona, SpainPosts: 361 admin
    @rbrinton, @MarthaDeevy, @efoehr, this is one of the potential breakthroughs that was discussed at the lab. I would be interested in your take: Is this enough of a breakthrough to advance longevity? And this is unlikely to be accomplished in the absence of an XPRIZE competition?
  • efoehrefoehr Posts: 8
    Constant monitoring of thousands (maybe hundreds of thousands or millions) of people to measure aging could lay the foundation for therapies. This effort would give a deep cross section of the aging population. A longitudinal clinical trial of aging would take decades to complete. But a cross-sectional clinical study design could be completed in a few years. The key is to collect and analyze massive amounts of data across many age groups and other demographics. The regulators in USA, Europe, and Asia would need to accept this type of data as clinical proof of safety and efficacy. This constant monitoring approach could be Step One in the ultimate XPrize to find a therapy to slow the aging process.
Sign In or Register to comment.